"For 3 decades, the staff of Louisville Metabolic and Atherosclerosis Research Center has conducted quality research involving over 500 clinical trials. While we often focus on treatments for metabolic disorders of cholesterol, triglycerides, diabetes mellitus, and obesity, we also conduct trials to evaluate new treatments for fatty liver, migraine headaches, arthritis, gout, pain, overactive bladder, and other disorders."

During the past decade, L-MARC Research Center conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 40 clinical trials were completed, i.e. on average, 81.6% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 24 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "L-MARC Research Center" #1 sponsor was "Pfizer" with 18 trials, followed by "Eli Lilly and Company" with 10 trials sponsored, "Esperion Therapeutics, Inc." with 4 trials sponsored, "Louisville Metabolic and Atherosclerosis Research Center" with 4 trials sponsored and "Allergan" with 4 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "L-MARC Research Center" #1 collaborator was "California Raisin Marketing Board" with 2 trials as a collaborator, "Daiichi Sankyo, Inc." with 2 trials as a collaborator, "Medpace, Inc." with 2 trials as a collaborator, "Provident Clinical Research" with 2 trials as a collaborator and "The Cleveland Clinic" with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "L-MARC Research Center" are "Obesity" (9 trials), "Type 2 Diabetes Mellitus" (7 trials), "Hypercholesterolemia" (6 trials), "Diabetes Mellitus, Type 2" (5 trials) and "Overweight" (5 trials). Many other conditions were trialed in "L-MARC Research Center" in a lesser frequency.

Most popular intervention types in "L-MARC Research Center" are "Drug" (68 trials), "Other" (10 trials), "Biological" (6 trials), "Behavioral" (3 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Tirzepatide" (4 trials), "Olezarsen" (3 trials), "ARI-3037MO" (2 trials) and "Atorvastatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "L-MARC Research Center" are 78 trials for "All" genders.

Currently, there are NaN active trials in "L-MARC Research Center". undefined are not yet recruiting, 6 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 56 completed trials in L-MARC Research Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in L-MARC Research Center, 2 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 4 trials that are defined as “Not Applicable".